EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer

Amelia Acha-Sagredo, Pietro Andrei, Kalum Clayton, Emma Taggart, Carlotta Antoniotti, Chloé A Woodman, Hassnae Afrache, Constance Fourny, Maria Armero, Hafsa Kaja Moinudeen, Mary Green, Nisha Bhardwaj und 25 weitere

Cancer Cell · 2025-02 · 43 (2) · 292-307.e7

DOI: 10.1016/j.ccell.2024.12.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-02. Verfasst von Amelia Acha-Sagredo und 36 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Systems Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Centre for Cancer Evolution, Bart's Cancer Institute, Queen Mary …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors, Interferons. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, European Commission, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fewer than 50% of metastatic deficient mismatch repair (dMMR) colorectal cancer (CRC) patients respond to immune checkpoint inhibition (ICI). Identifying and expanding this patient population remains a pressing clinical need. Here, we report that an interferon-high immunophenotype locally enriched in cytotoxic lymphocytes and antigen-presenting macrophages is required for response. This immunophenotype is not exclusive to dMMR CRCs but comprises a subset of MMR proficient (pMMR) CRCs. Single-cell spatial analysis and in vitro cell co-cultures indicate that interferon-producing cytotoxic T cells induce overexpression of antigen presentation in adjacent macrophages and tumor cells, including MHC class II invariant chain CD74. dMMR CRCs expressing high levels of CD74 respond to ICI and a subset of CD74 high pMMR CRC patients show better progression free survival when treated with ICI. Therefore, CD74 abundance can identify the constitutive interferon-high immunophenotype determining clinical benefit in CRC, independently of tumor mutational burden or MMR status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmunotherapyImmune Checkpoint InhibitorsInterferonsHumansImmunophenotypingHistocompatibility Antigens Class IIDNA Mismatch RepairAntigens, Differentiation, B-LymphocyteMacrophagesT-Lymphocytes, CytotoxicFemaleMaleAntigen Presentation

Stichwörter der Autor:innen

CD74antigen presentationcolorectal cancerimmunotherapyinterferonmarker of responsepatient stratificationspatial transcriptomicstumor immune microenvironment

Substanzen

Histocompatibility Antigens Class IIImmune Checkpoint InhibitorsInterferonsinvariant chainAntigens, Differentiation, B-Lymphocyte

Autor:innen und Institutionen

  • Cancer Systems Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Centre for Cancer Evolution, Bart's Cancer Institute, Queen Mary University London, London EC1M 6AU, UK.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 1UL, UK.
  • Centre for Inflammation Biology and Cancer Immunology, King's College London, London SE1 1UL, UK; Molecular Immunology Laboratory, Francis Crick Institute, London NW1 1AT, UK.
  • Cancer Systems Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Experimental Histopathology, The Francis Crick Institute, London NW1 1AT, UK.

Förderung

  • Medical Research Council
  • European Commission
  • Wellcome Trust
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Cancer Research UK
  • Francis Crick Institute
  • National Institute for Health and Care Research
  • UCLH Biomedical Research Centre

Zitieren

APA

Acha-Sagredo, A., Andrei, P., Clayton, K., Taggart, E., Antoniotti, C., Woodman, C. A., Afrache, H., Fourny, C., Armero, M., Moinudeen, H. K., Green, M., Bhardwaj, N., Mikolajczak, A., Rodriguez-Lopez, M., Crawford, M., Connick, E., Lim, S., Hobson, P., Linares, J., …, & Ciccarelli, F. D. (2025). A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer Cell, 43(2), 292-307.e7. https://doi.org/10.1016/j.ccell.2024.12.008

Vancouver

Acha-Sagredo A, Andrei P, Clayton K, Taggart E, Antoniotti C, Woodman CA, et al. A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer Cell. 2025;43(2):292-307.e7. doi:10.1016/j.ccell.2024.12.008

BibTeX
@article{AchaSagredo2025,
  author = {Acha-Sagredo, Amelia and Andrei, Pietro and Clayton, Kalum and Taggart, Emma and Antoniotti, Carlotta and Woodman, Chloé A and Afrache, Hassnae and Fourny, Constance and Armero, Maria and Moinudeen, Hafsa Kaja and Green, Mary and Bhardwaj, Nisha and Mikolajczak, Anna and Rodriguez-Lopez, Maria and Crawford, Marg and Connick, Emma and Lim, Steven and Hobson, Philip and Linares, Josep and Ignatova, Ekaterina and Pelka, Diana and Smyth, Elizabeth C and Diamantis, Nikolaos and Sosnowska, Dominika and Carullo, Martina and Ciraci, Paolo and Bergamo, Francesca and Intini, Rossana and Nye, Emma and Barral, Patricia and Mishto, Michele and Arnold, James N and Lonardi, Sara and Cremolini, Chiara and Fontana, Elisa and Rodriguez-Justo, Manuel and Ciccarelli, Francesca D},
  title = {A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {2},
  pages = {292--307.e7},
  doi = {10.1016/j.ccell.2024.12.008}
}
Kostenlos starten →